VSEE VSEE HEALTH, INC.
Price Chart
Executive Summary
VSee Health entered into a Standby Equity Purchase Agreement (SEPA) with YA II PN, Ltd. for up to $10M in common stock sales at a 3% discount to the lowest VWAP, issued 532,481 commitment shares upfront, and committed to file a resale registration statement. This comes just 6 days after spinning off its VSee Lab subsidiary (which contributed ~50% of FY2025 revenue) and deleveraging the balance sheet via a management-led transaction. The SEPA effectively replaces the lost revenue-generating capacity with a highly dilutive equity line, potentially flooding the market with shares up to ~20% of the current float at heavy discount.
Key Financial Metrics
Actionable Insight
The SEPA creates persistent downward pressure as the company can repeatedly sell shares at a discount. Monitor for the first Advance Notice and the effectiveness of the resale registration statement—once effective, the investor can immediately sell into the market, likely capping any rally. The combination of a halved revenue base and this equity line suggests the company is burning cash and has limited organic funding alternatives. Short sellers should watch for volume spikes following registration statement effectiveness.
Key Facts
- SEPA allows VSee to require YA II PN to purchase up to $10M of common stock at 97% of the lowest daily VWAP over a 3-day pricing period
- Company issued 532,481 Commitment Shares (1% of $10M Commitment Amount / pre-deal VWAP) as a fully earned fee
- Exchange Cap set at 9,715,140 shares (19.99% of pre-deal outstanding), with no stockholder approval threshold met unless average price exceeds $0.1878/share
- SEPA runs until June 2, 2029, and the company may terminate on 5 trading days' notice
- Transaction was completed just 6 days after VSee spun off VSee Lab to former co-CEO Milton Chen, shrinking revenue by ~50% (from $14.6M to ~$7.3M in FY2025)
- Current market cap is ~$8M; the $10M commitment amount is 125% of market cap, implying maximum potential dilution of over 100% of current shares if fully drawn at current prices
Financial Impact
Potential dilution up to 20% of shares outstanding (Exchange Cap) without stockholder approval, and the $10M commitment exceeds the company's current $8M market cap, creating severe dilution risk. The 3% discount to VWAP plus the up-front commitment shares (532,481) impose an immediate cost of capital of ~5-10% on any draws.
Risk Factors
- Immediate dilution of up to 19.99% of shares outstanding without stockholder approval
- Potential for substantially more dilution if stockholder approval is obtained or the average price threshold ($0.1878) is exceeded
- The Yorkville-type SEPA structure is known to create 'death spiral' dynamics where increased selling depresses the stock, triggering more shares to be issued at lower prices
- Revenue base just halved (~$7.3M to ~$7.3M post-spin), making the company even more dependent on equity financing to sustain operations
- Nasdaq continued listing may be at risk if the stock price declines further from current $0.16 level (near potential compliance thresholds)
Market Snapshot
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001185185-26-002467 |
| Document: vsee8k061026.htm | 0001185185-26-002467 |
| Document: 0001185185-26-002467-index-headers.html | 0001185185-26-002467 |
| Document: 0001185185-26-002467-index.html | 0001185185-26-002467 |
| Document: 0001185185-26-002467.txt | 0001185185-26-002467 |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access